George Pope
About George Pope
George Pope is a Group Leader in Preclinical Safety at Adaptimmune, where he has worked since 2020. He holds a PhD in Neuroendocrinology from the University of Bristol and has over six years of experience in the cell therapy field.
Work at Adaptimmune
George Pope has served as Group Leader - Preclinical Safety at Adaptimmune since 2020. In this role, he oversees preclinical safety assessments, contributing to the development of cell therapies. Prior to this position, he worked as a Senior Scientist at Adaptimmune from 2016 to 2020, where he focused on advancing research initiatives within the organization. His tenure at Adaptimmune has allowed him to leverage his expertise in T cell biology and project management.
Education and Expertise
George Pope earned a Doctor of Philosophy (PhD) in Neuroendocrinology from the University of Bristol, completing his studies from 2008 to 2012. He also holds a Bachelor of Science (BSc) in Molecular and Cellular Biology from the University of Kent, which he obtained from 2003 to 2006. His educational background has equipped him with a strong foundation in biological sciences, particularly in the fields of immunotherapy and biotechnology.
Background
Before his current role, George Pope accumulated significant research experience at the University of Bristol. He worked as a Research Assistant from 2007 to 2008 and later as a Research Postgraduate from 2008 to 2012. Additionally, he served as a Research Assistant in Hormone Signalling from 2013 to 2014. His diverse roles in academia have contributed to his extensive knowledge in cell therapy and immunology.
Achievements
George Pope has presented his research at the ASGCT Annual Meeting in 2022, showcasing his contributions to the field of immunotherapy. He has authored a publication focusing on IL-7 and CCL19 expression in T-cells, reflecting his active involvement in scientific research and dissemination of knowledge. His work has contributed to advancements in understanding T cell biology and its applications in cell therapy.